Skip to content
Search

Latest Stories

Uber to Pay £ 1.5 million for Sexual Abuse Claims

Ride-sharing application, Uber is near a final settlement related to some sexual harassment and discrimination claims made by its staff. The company will pay 1.5 million pounds to 56 present and former employees who claim that they were the victims of sexual harassment.

The 56 employees also get around 8530.22 pounds as part of a class action involving 485 people who claimed discrimination. The payment is expected to be a portion of the company’s total settlement of 7.75 million pounds agreed in March this year.


The class action case is based in the US and being moved by two Latina engineers who alleged that they are paid less than that of their Asian, white, and male colleagues. The duo registered a legal claim against Uber in October 2017 and claimed that they faced harassment and bitter work environment due to their gender and ethnic origin.

Both parties including the company and the claimants have to get the necessary approval from the court to get the payout. In addition to legal battle, Uber is being questioned by US officials for gender bias.

A hearing will be held at a court in California to make final approval of the settlement in November, this year.

The sexual harassment and discrimination claims are among a series of legal issues that Uber's administration had faced in the last year.

Last month, Liane Hornsey, head of Uber’s Human Resource Department left her job after an internal probe into how Liane handled racial discrimination claims as a company human resource department head.

Meanwhile, some of the issues of the Uber have been solved recently which include loss of its license to function in London and legal suit in the US registered by a lady who alleged Uber staff of improperly having her medical records after she was raped by a driver in India.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less